Merck vs. Sun Pharma: Consent Judgment in DIFICID® Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Merck Sharp & Dohme, LLC et al. v. Sun Pharmaceutical Industries, Inc. |
| Case Number | 2:25-cv-01424 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Feb 2025 – May 2025 77 days |
| Outcome | Plaintiff Win – Permanent Injunction |
| Patents at Issue | |
| Accused Products | Sun’s ANDA No. 220102 generic DIFICID® product |
Case Overview
The Parties
⚖️ Plaintiff
Subsidiary of Merck & Co., Inc., holding commercialization and patent rights for DIFICID® (fidaxomicin), an antibiotic for CDAD.
🛡️ Defendant
U.S. arm of a global generic pharmaceutical manufacturer, filed ANDA No. 220102 seeking FDA approval for a generic DIFICID® product.
The Patents at Issue
This case involved four U.S. patents covering the fidaxomicin compound and its formulation:
- • US7,906,489 — Fidaxomicin compound and formulation
- • US7,378,508 — Fidaxomicin compound and formulation
- • US7,863,249 — Fidaxomicin compound and formulation
- • US8,859,510 — Fidaxomicin compound and formulation
Developing a generic drug?
Check if your product might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
The District Court entered a consent judgment and permanent injunction on May 12, 2025, by stipulation of the parties. This outcome prohibits Sun Pharmaceutical Industries, Inc. from making, using, selling, offering to sell, importing, or distributing any product covered by ANDA No. 220102 without Merck’s explicit authorization. No monetary damages were awarded.
Key Legal Issues
The case was resolved rapidly in just 77 days, directly from complaint to stipulated consent judgment. This swift resolution, without any substantive motions being litigated, suggests that Merck’s patent portfolio presented formidable barriers to a successful invalidity challenge by Sun. The focus of the resolution was entirely on injunctive relief, rather than damages.
Filing a pharmaceutical patent?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this therapeutic space
- See which companies are most active in antibiotic IP
- Understand claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own generic drug or compound.
- Input your drug compound or formulation details
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Fidaxomicin compound & formulation
4 Patents Affirmed
Protecting DIFICID®
Strategic Resolution
Consent judgment without trial
✅ Key Takeaways
For Patent Attorneys & Litigators
Consent judgments with no authorized entry date represent optimal outcomes for branded pharmaceutical plaintiffs in ANDA litigation.
Search related case law →Multi-patent portfolio enforcement creates compounding invalidity burden for generic challengers.
Explore precedents →For R&D Teams
Comprehensive FTO analysis before ANDA investment is essential when target products carry multi-patent estates.
Start FTO analysis for my product →Rapid internal claim mapping post-complaint filing enables informed early resolution decisions.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.